Combo therapy ‘beneficial’ in metastatic prostate cancer
Trial results show improved clinical outcome in a subset of men with castration-resistant disease, researchers say
AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.
Men with metastatic castration-resistant prostate cancer who have lost a copy of the PTEN gene might improve their progression-free survival (PFS) with a combination of ipatasertib and abiraterone plus prednisone, researchers say.
Results of the phase 3 IPATential150 trial were reported at the European Society for Medical Oncology (ESMO) virtual congress 2020.
About 40-50% of tumours in metastatic castration-resistant disease have hyperactivation of the P13K/AKT signalling pathway that promotes prostate cancer owing to loss of the PTEN gene and this can be made worse by androgen receptor blockade.
